Cargando…
Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial
SIMPLE SUMMARY: We report the final results of a multicenter, prospective, 2-arm trial in a real world setting for patients with metastatic castration resistant prostate cancer. A number of 675 patients were allocated by center-based cluster-randomization to arm A with adherence enhancing measures o...
Autores principales: | Suttmann, Henrik, Gleissner, Jochen, Huebner, Andreas, Mathes, Tim, Baurecht, Werner, Krützfeldt, Katrin, Sweiti, Hussein, Feyerabend, Susan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564106/ https://www.ncbi.nlm.nih.gov/pubmed/32911627 http://dx.doi.org/10.3390/cancers12092550 |
Ejemplares similares
-
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
por: Ohlmann, Carsten-Henning, et al.
Publicado: (2022) -
Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
por: Ohlmann, Carsten-Henning, et al.
Publicado: (2023) -
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
por: Tolcher, A. W., et al.
Publicado: (2012) -
Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
por: Yang, Zhenyu, et al.
Publicado: (2021) -
Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
por: Tsujino, Takuya, et al.
Publicado: (2023)